Cellectis SA
CLLS3.570USD
+0.070+2.00%
終値 02/06, 16:00（ET）15分遅れの株価
258.20M時価総額
損失額直近12ヶ月PER
詳細情報 Cellectis SA 企業名
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SAの企業情報
企業コードCLLS
会社名Cellectis SA
上場日Feb 06, 2007
最高経営責任者「CEO」Sourdive (David J.D)
従業員数224
証券種類Depository Receipt
決算期末Feb 06
本社所在地8, rue de la Croix Jarry
都市PARIS
証券取引所NASDAQ OMX - NASDAQ BASIC
国France
郵便番号75013
電話番号33181691600
ウェブサイトhttps://www.cellectis.com/
企業コードCLLS
上場日Feb 06, 2007
最高経営責任者「CEO」Sourdive (David J.D)
Cellectis SAの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Jan 4
更新時刻: Sun, Jan 4
株主統計
種類
株主統計
株主統計
比率
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
他の
86.98%
株主統計
株主統計
比率
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
他の
86.98%
種類
株主統計
比率
Investment Advisor
7.72%
Hedge Fund
6.09%
Investment Advisor/Hedge Fund
0.42%
Research Firm
0.22%
他の
85.55%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
70
10.10M
29.55%
--
2025Q3
77
10.10M
29.65%
-3.45M
2025Q2
79
13.55M
35.05%
-1.95M
2025Q1
82
15.50M
31.47%
-7.25M
2024Q4
86
16.67M
24.79%
+2.93M
2024Q3
104
15.35M
28.39%
+1.55M
2024Q2
103
13.80M
26.34%
-48.27K
2024Q1
112
13.82M
26.53%
-5.23M
2023Q4
124
13.74M
31.43%
+147.34K
2023Q3
142
13.59M
44.11%
-2.54M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Long Focus Capital Management LLC
4.12M
5.7%
-594.03K
-12.59%
Sep 30, 2025
B Group, Inc.
3.28M
4.54%
+25.00K
+0.77%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
BlackRock Institutional Trust Company, N.A.
337.45K
0.47%
+337.45K
--
Dec 31, 2025
Nomura Investment Management Business Trust
226.88K
0.31%
--
--
Sep 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jun 30, 2025
Citadel Advisors LLC
221.96K
0.31%
+221.96K
--
Sep 30, 2025
LPL Financial LLC
85.15K
0.12%
-515.00
-0.60%
Sep 30, 2025
Morgan Stanley & Co. International Plc
83.39K
0.12%
+10.20K
+13.94%
Sep 30, 2025
Millennium Management LLC
57.74K
0.08%
+22.08K
+61.92%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
比率0%
Avantis International Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
